Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder

Abstract

Background. Post-Traumatic Stress Disorder (PTSD) is an important public health challenge typically treated with trauma-focused psychotherapy and Selective Serotonin Reuptake Inhibitors (SSRIs). However, high rates of residual symptoms associated with these standard treatments have led to a renewed interest in psychedelic-assisted therapies. Aim. This review attempts to examine emerging psychedelic therapies in the management of PTSD, with a primary focus on 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ketamine. Material and methods. A literature search was carried out using PubMed, Google Scholar, and Scopus to identify relevant studies using keywords such as 'PTSD', 'MDMA', 'psychedelics', 'ketamine', 'psychedelic-assisted therapy', 'neuroplasticity', and 'fear extinction'. Results. Psychedelics induce neuroplasticity and augment fear extinction, primarily through the AMPAR-BDNF-TrkB-mTOR pathway and 5-HT2A receptors. MDMA-assisted therapy demonstrates high efficacy, with a trial showing that 67% of participants no longer met PTSD criteria at the study endpoint. Psilocybin effectively treats common comorbidities like anxiety and treatment-resistant depression. Ketamine offers rapid symptom alleviation, making it notably beneficial for treatment-resistant cases with a high risk of self-harm and suicide. Conclusions. Psychedelic therapies, particularly MDMA-assisted therapy, represent a potential breakthrough by targeting the underlying causes of PTSD rather than merely suppressing symptoms. In spite of current regulatory problems, they hold meaningful promise, pointing out the need for standardized treatment protocols to ensure safety and reproducibility in future research.

In the evidence

This study is part of the evidence base for 4 syntheses in the library. Here is how each one recorded it.

• State of the evidence: Ketamine for PTSD ↑Supports

  Reports that ketamine offers rapid symptom alleviation, notably beneficial for treatment-resistant cases with high risk of self-harm and suicide, while MDMA-assisted therapy showed high efficacy.

  Synthesized September 21, 2026

• State of the evidence: Ketamine for anxiety ↑Supports

  Ketamine offers rapid symptom alleviation in PTSD, making it notably beneficial for treatment-resistant cases with high risk of self-harm and suicide.

  Synthesized September 21, 2026

• State of the evidence: Psilocybin for PTSD ↑Supports

  Reports that psychedelics induce neuroplasticity and augment fear extinction, that MDMA-assisted therapy showed 67% of participants no longer meeting PTSD criteria at endpoint, and that psilocybin effectively treats common comorbidities like anxiety and treatment-resistant depression.

  Synthesized September 21, 2026

• State of the evidence: Psilocybin for anxiety ↑Supports

  Psilocybin effectively treats common comorbidities like anxiety and treatment-resistant depression, though the review's primary focus is MDMA-assisted therapy for PTSD.

  Synthesized September 21, 2026

Comparable studies

Other narrative reviews on psilocybin for PTSD, most cited first.